Key Takeaways
- The federal government is now acknowledging cannabis has medical value, but this could lead to increased control rather than true legalization.
- While Schedule III may offer some tax relief and open research opportunities, it does not provide comprehensive protections for small operators or legalize adult use.
- The medical cannabis movement was built by patients and activists, not corporations, and the same institutions that denied its value are now trying to regulate it.
- The fear is that strict regulations will favor large corporations, leaving small operators behind and potentially erasing their contributions to the industry.
- Real cannabis reform must protect small businesses, include criminal justice reform, and recognize that cannabis is more than just medicine.
NORTH AMERICA – For decades, cannabis activists, patients, legacy operators, caregivers, cultivators, medical collectives, and underground healers fought to force the federal government to admit one basic truth: cannabis has medical value.
People were arrested for saying it. Families were raided for growing it. Patients were treated like criminals for using it. Small operators lost homes, licenses, freedom, custody, bank accounts, businesses, and years of their lives because the federal government insisted cannabis belonged in Schedule I, right next to substances it claimed had no accepted medical use.
Now, after all that damage, the federal government is finally admitting what patients have known forever.
Cannabis is medicine.
But here is the part too many people are missing: that admission may not be the finish line. It may be the opening move in a much bigger power grab.
For years, we at Beard Bros Pharms have warned that the activism built around proving cannabis is medical would one day be weaponized against the very community that fought for it.We hoped we were wrong. We still hope we are wrong. But with federal rescheduling, medical-only carveouts, DEA hearings, and the steady march toward Schedule III, it sure feels like that day is here.
How Medical Recognition Could Become a Federal Power Grab
The federal government spent decades telling us cannabis was not medicine. The federal government appears ready to classify cannabis as medicine. This means federal agencies will control it, subjecting it to pharmaceutical standards, prescription systems, and corporate capital. These regulatory structures are often too costly for most small operators to afford.
That is not liberation.
That is not justice.
That is not legalization.
That is a trap door dressed up as reform.
The Same Government That Criminalized Cannabis Now Wants to Regulate It as Medicine
Let’s be brutally honest. The federal government did not discover cannabis has medical value in 2024, 2025, or 2026. It did not need another committee, another hearing, another agency memo, or another stack of expert testimony to know what millions of patients, veterans, cancer survivors, epilepsy families, pain patients, AIDS patients, growers, caregivers, and legacy operators have been saying for generations.
The government knew.
It just refused to admit it.
And while it refused, people went to prison. The war on cannabis separated parents from their children and denied patients access to life-saving medicine. It overpoliced communities, targeting Black, Brown, poor, rural, and legacy cannabis communities the hardest. The law treated small farmers and caregivers like traffickers while real corporate players waited safely on the sidelines for their opportunity.
Now the same federal system that punished people for cannabis wants to decide who gets to participate in the future of cannabis.
That should make every small operator in the country nervous.
When a Rallying Cry Becomes a Cage
Because when the government finally says, “Fine, cannabis has medical value,” the next sentence may be, “And now we control the medicine.”
That is the danger.
For years, “cannabis is medicine” was a rallying cry against prohibition. It was a shield for patients. It was a moral argument. It was how this movement broke through decades of propaganda. But in the hands of federal regulators, that same phrase can become a cage.
If cannabis is only medicine, then who gets to grow it?
Who gets to manufacture it?
Who gets to sell it?
Who gets to prescribe it?
Who gets to insure it?
Who gets access to capital?
Who gets taxed differently?
Who gets left outside the system?
And maybe most importantly, who do we erase from the story after they’ve done the dangerous work that made the industry possible?
Schedule III May Help Some Operators, But It Does Not Save the Industry
Let’s give Schedule III its due. Moving cannabis out of Schedule I would be historic. It could reduce some of the tax pressure tied to 280E. It could open doors for more research. It could help some state-licensed medical cannabis operators. It could create a path for certain businesses to survive after years of federal tax abuse.
No serious person should pretend that 280E relief does not matter. For small operators, 280E has been a financial meat grinder. It has punished legal businesses for existing. It has forced cannabis companies to pay federal taxes like drug traffickers while trying to operate like compliant local businesses.
So yes, Schedule III could help.
But help is not the same as freedom.
Why Schedule III Falls Short of Real Reform
Schedule III does not deschedule cannabis. It does not legalize adult use. It does not repair the harms of prohibition. It does not automatically protect small operators. It does not create interstate fairness. It does not stop federal agencies from building a new medical regulatory framework that favors the biggest, wealthiest, most lawyered-up players in the room.
That is the part the headlines keep skipping.
Schedule III is being sold to the public as progress. And in some ways, it is. But for small operators, progress with strings attached can quickly become a noose.
Moving cannabis into a pharmaceutical-style category without real protections for state markets, adult-use operators, legacy businesses, social equity licensees, small farmers, caregivers, and independent retailers could lead the industry into a system designed for consolidation.
And once that system is built, good luck getting invited back in.
Patients and Activists Built the Medical Argument, Not Corporations
Big Pharma didn’t build the medical cannabis movement. Wall Street didn’t build it. MSOs didn’t build it. Federal regulators in suits pretending they just noticed the plant works didn’t build it.
It was built by patients.
It was built by caregivers.
It was built by people growing in closets, garages, basements, backyards, warehouses, and mountain communities before there was any legal protection at all.
AIDS activists in San Francisco built it. Cancer patients who needed appetite and pain relief built it. Parents fighting for children with seizures built it. Veterans trying to sleep without being buried under prescription pills built it. People willing to risk jail because the law was wrong and the plant was helping built it.
The Government Didn’t Invent the Medical Argument—It Denied It
That history matters because the federal government is now using the language of medicine as if it invented the concept.
It did not.
The government denied the medical value of cannabis for decades. The cannabis community proved it. Patients proved it. Legacy operators proved it. Small operators supplied the medicine when the system refused to.
The very institutions that once ignored, mocked, arrested, taxed, raided, and punished the cannabis community are now moving to federally recognize it as medicine. However, they are doing so under a framework that may only benefit the interests that were absent when the risk was real.
That is the betrayal small operators feel in their bones.
Small Operators Are Watching the Door Close
From a small operator’s point of view, the fear is not abstract. It is not paranoia. It is based on what has already happened in state after state.
Every time cannabis regulation increases, regulators tell the people who fought hardest to create the market to pay more, wait longer, and hire more lawyers. These pioneers must meet more standards, buy more software, and survive more delays, all while competing against better-funded companies that can lose money longer than any independent operator can stay alive.
Compliance is important. Testing is important. Consumer safety is important. Responsible operations matter.
But let’s not pretend all regulation is created equal.
Some regulation protects consumers.
Some regulation protects monopolies.
The Velvet Rope of “Neutral” Regulation
Some regulation is written in a way that sounds neutral but functions like a velvet rope outside the club. Technically, anyone can apply. Practically, only the rich get in.
That is what small cannabis operators are worried about with federal rescheduling. Not because they oppose medical cannabis. Not because they oppose patient access. Not because they oppose safety. But because they have seen this movie before.
First, the government says it wants order.
Then it says small operators need to professionalize.
Then it says compliance costs are just part of doing business.
Then the banks, insurers, landlords, investors, attorneys, testing labs, consultants, and regulators all get paid before the grower, the processor, the brand, or the retailer can breathe.
Then the big companies consolidate.
Then the people who built the culture are told they should have scaled faster.
That is not a free market. That is a controlled demolition.
Adult-Use Cannabis Does Not Fit Cleanly Inside Schedule III
One of the biggest problems with Schedule III is obvious: adult-use cannabis does not fit neatly into a prescription drug framework.
Millions of adults use cannabis legally under state law for wellness, relaxation, creativity, sleep, stress, pain, recovery, social use, spiritual use, and plain old enjoyment. Some use it medically without a medical card because they live in adult-use states. Some use it because the formal medical system is too expensive, too restrictive, too stigmatized, or too difficult to navigate.
That is reality.
Cannabis is not just one thing. It is medicine. It is wellness. It is culture. It is agriculture. It is craft. It is adult choice. It is community. It is ritual. It is harm reduction. It is also a product category that states have already regulated for years.
Trying to force all of that into a federal medical box is not just bad policy. It is dishonest.
How a Medical-Only Framework Picks Winners
If federal rescheduling only gives clean protection to state medical programs or future FDA-style products while adult-use operators remain exposed, then the government is not solving the cannabis problem. It is picking winners.
Medical operators may receive a clearer federal path.
Adult-use operators may remain stuck in conflict.
Big companies with medical licenses may get tax relief, capital access, and legitimacy.
Small adult-use businesses may continue fighting uphill under federal uncertainty.
That split could reshape the entire industry.
And it would not be based on who served patients first, who built trust, who survived prohibition, or who created value in their communities. It would be based on who fits into the federal government’s preferred category.
That should bother everyone who claims to care about cannabis reform.
Big Business Has Been Waiting for This Moment
Cannabis has always had two timelines.
The first timeline belongs to the people who lived the risk. The patients, growers, caregivers, prisoners, activists, independent retailers, small brands, and legacy operators who carried the movement when cannabis was still treated like a criminal threat.
The second timeline belongs to big business. The investors, pharmaceutical interests, alcohol companies, tobacco companies, consumer packaged goods giants, hedge funds, lobbyists, and corporate operators waiting for the risk to drop low enough and the rules to become friendly enough.
Schedule III may be the bridge between those two timelines.
When an Industry Gets “Cleaned Up” for Corporate Entry
Once cannabis is federally acknowledged as medicine, the biggest players can step in and say they are not entering a controversial industry. They are investing in healthcare. They are scaling regulated medicine. They are bringing compliance, safety, research, and national infrastructure.
That language sounds clean. It also sounds expensive.
Small operators know what happens when an industry gets cleaned up for corporate entry. The culture gets repackaged. The margins get squeezed. The rules get rewritten. The people with deep pockets call it maturity. The people who built the foundation call it theft.
And make no mistake, cannabis has already been moving in that direction. Federal rescheduling could accelerate it.
If cannabis becomes a medical commodity controlled through federal structures, prescription pathways, institutional capital, and pharmaceutical-style regulation, then the future may not belong to the best growers, the most trusted brands, or the people closest to the community.
It may belong to whoever can afford the paperwork.
That is not what activists fought for.
The Cannabis Community Should Not Apologize for Wanting More Than Medical Access
One of the most frustrating parts of this moment is the way cannabis reform gets narrowed into the safest possible language.
Medical access matters. Research matters. Veterans matter. Patients matter. Nobody is disputing that.
But cannabis freedom cannot stop at medical permission slips.
The plant does not become legitimate only when a doctor, federal agency, or pharmaceutical company says so. Adults should not have to pretend every use is clinical to deserve legal access. And small operators should not have to squeeze themselves into a medical-only model just to avoid being treated like criminals.
Cannabis is bigger than medicine.
Cannabis Is More Than a Prescription Category
That does not weaken the medical argument. It strengthens the truth.
All cannabis use may have wellness value for many consumers, but not all cannabis use should be forced through a federal medical framework. People use cannabis to avoid alcohol. They use it instead of pills. They use it to sleep. They use it to eat. They use it to manage stress. They use it after work. They use it in community. They use it because it improves their quality of life.
That is not something the federal government should get to reduce to a prescription category.
A real cannabis policy would recognize the full spectrum of use. It would protect patients, adult consumers, small businesses, legacy operators, caregivers, researchers, and state-regulated markets. It would deschedule cannabis and build a fair framework around public health, equity, agriculture, commerce, and personal liberty.
Schedule III does not do that.
The Federal Government Owes the Cannabis Community More Than a Medical Carveout
After decades of prohibition, the federal government does not get to pat itself on the back for admitting cannabis has medical value.
That admission is late. Very late.
The government owes more than rescheduling. It owes repair.
It owes expungement. It owes clemency. It owes tax fairness. It owes banking access. It owes protection for state-legal operators. It owes pathways for legacy operators. It owes meaningful support for people harmed by enforcement. It owes clarity for adult-use markets. It owes an end to the federal contradiction that lets states build cannabis industries while Washington keeps the plant federally controlled.
Most of all, it owes humility.
Because the people in the cannabis community were right.
The government was wrong.
That should matter.
Prohibition Learning How to Wear a Lab Coat
Instead, the risk is that federal agencies will now use the community’s victory against it. They will take the medical argument activists built under threat of prison and use it to justify a new system of control. They will say cannabis is legitimate only when federally managed, medically categorized, professionally dispensed, corporately financed, and tightly restricted.
That is not justice.
That is prohibition learning how to wear a lab coat.
What Small Operators Need to Demand Right Now
Small operators cannot afford to sit back and hope federal rescheduling works out. Hope is not a strategy. We have seen what happens when cannabis policy is written without the people who actually understand cannabis.
The industry needs to demand protections now.
Any federal cannabis reform must protect existing state-licensed businesses, including adult-use operators. It must prevent Schedule III from becoming a backdoor medical monopoly. It must preserve patient access outside pharmaceutical-only channels. It must include small business protections, legacy pathways, and fair competition rules. It must address 280E without handing the biggest benefits only to companies with the cleanest medical fit. It must include criminal justice reform, expungement, clemency, and real repair for communities harmed by prohibition.
Cannabis Is Medicine, But Not Only Medicine
It also must respect that cannabis is not just a pharmaceutical input.
Cannabis is a plant. Cannabis is an agricultural product. Cannabis is a wellness product. Cannabis is an adult-use product. Cannabis is a cultural product. Cannabis is medicine, yes, but it is not only medicine.
That distinction is everything.
If the federal government refuses to recognize that, then Schedule III could become one more chapter in the long history of cannabis policy helping the powerful while punishing the people closest to the plant.
This Is Why the DEA Hearing Matters
The DEA rescheduling hearing matters because it is not just about where cannabis sits on a federal schedule. It is about who gets to define cannabis in America.
Will patients, consumers, legacy operators, small businesses, farmers, scientists, and communities define the future of cannabis?
Or will federal agencies, pharmaceutical logic, corporate consolidation, and prohibitionist holdovers—who still don’t respect the plant or the people who fought for it—define its future?
That is the real question.
A Hearing That Sidelines the Movement Is a Warning Sign
And when the process fails to meaningfully include pro-cannabis voices, the cannabis community has every reason to question the legitimacy of the conversation. How do you hold a hearing about the future of cannabis and sideline the people who built the movement?
How do you discuss medical value without centering patients?
How do you discuss regulation without centering the operators already regulated by states?
How do you discuss reform while excluding the reform community?
That is not a balanced process. That is a warning sign.
We Hope We Are Wrong
At Beard Bros Pharms, we would love to be wrong about this.
We would love to see cannabis moved to Schedule III become a bridge to more reform, not a cage for the industry. We would love to see small operators protected, patients respected, adult-use markets clarified, legacy businesses included, and federal agencies finally act with the humility this history demands.
We would love to see cannabis policy move toward justice instead of consolidation.
But hope does not erase what we are seeing.
Medical Recognition Should Not Become a New Form of Control
The federal government spent decades criminalizing cannabis. Now it is finally admitting cannabis has medical value. But instead of ending prohibition, it appears to be building a new framework where medical recognition becomes the justification for more federal control.
That is the danger.
Activists could now use the same argument that protected patients to narrow the market. The same medical truth that helped defeat Schedule I could now build a Schedule III system favoring Big Pharma, MSOs, institutional investors, and federally approved operators over the small businesses and legacy communities that carried this industry through its hardest years.
Not Legalization. Not Freedom. Not Justice.
For decades, cannabis activists fought against a government that refused to admit the obvious, not so the plant could be handed to the highest bidder.
Patients did not risk arrest so federal agencies could turn around and tell them the only legitimate cannabis is the kind that fits neatly into a medical bureaucracy.
Small operators survived raids, stigma, taxes, banking bans, local bans, compliance chaos, and predatory competition. They didn’t do it just to watch big business repackage the industry under the banner of reform.
Cannabis is medicine.
But cannabis is not only medicine.
And if the federal government uses medical recognition as a weapon to control, limit, consolidate, or corporatize the plant, then the cannabis community needs to call it what it is.
Not legalization.
Not freedom.
Not justice.
Just another version of prohibition, polished up for the boardroom.
Frequently Asked Questions
Rescheduling cannabis to Schedule III would move it out of Schedule I, where it currently sits alongside substances the government claims have no accepted medical use. Schedule III would acknowledge cannabis has medical value, potentially easing 280E tax burdens and opening doors for more research. However, it does not deschedule cannabis, legalize adult use, or automatically protect small operators.
Schedule III still classifies cannabis as a controlled substance. It does not end federal prohibition, legalize adult use, repair the harms of past enforcement, or create interstate fairness. It simply moves cannabis to a less restrictive category, primarily benefiting medical and pharmaceutical-style operations.
Adult-use cannabis does not fit cleanly into a prescription drug model. If federal rescheduling only protects state medical programs or FDA-style products, millions of adults who use cannabis for wellness, relaxation, and personal choice—along with the businesses that serve them—could remain in a state of federal uncertainty.
